Legend Biotech Corporation
LEGN
Positions held
Your positionsLEGN isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Legend Biotech is positioned well within the biotechnology industry, focusing on innovative therapies that address unmet medical needs, which can lead to significant market opportunities.
- In Q2 2026, revenue increased by 27% compared to the prior quarter, reaching $387.5 million.
- Gross margin improved to 64.5% from 42.3% in the previous quarter.
- Despite recent revenue growth, Legend Biotech has faced significant operating losses, indicating challenges in achieving profitability.
- The company reported a net income loss of $54.3 million in Q1 2026, following a loss of $30.8 million in Q4 2025.
- The overall trend shows a negative score of -10.00, indicating bearish sentiment in the market.
Fundamentals
| Market cap | $3.64B | Enterprise value | $2.94B | Trailing P/E | — | Forward P/E | 17.82 |
| PEG | — | Price / book | 2.95 | Beta | 0.57 | Dividend yield | 0.00% |
| Revenue growth | 51.9% | Earnings growth | — | Gross margin | 56.6% | Operating margin | 14.9% |
| Profit margin | -7.2% | ROE | -8.1% | ROA | -1.9% | Debt / equity | 0.23 |
| Current ratio | 3.04 | Free cash flow | $27.19M | Analyst recommendation | buy | Mean target | $46.35 |
| 52w high | $37.50 | 52w low | $16.24 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $388M | $305M | $306M | $272M | $255M | — |
| Op margin | 14.9% | -16.3% | -6.7% | -16.0% | -8.6% | — |
| Net income | $33.2M | -$54.3M | -$30.8M | -$39.7M | -$125M | — |
| Gross margin | 64.5% | 42.3% | 59.7% | 57.7% | 61.6% | — |
| Gross profit | $250M | $129M | $183M | $157M | $157M | — |
| Operating income | $57.7M | -$49.8M | -$20.6M | -$43.5M | -$21.9M | — |
- Revenue +27% vs prior quarter ($388M vs $305M).
- Gross margin 64.5% (was 42.3% prior quarter).
- Operating margin expanded to 14.9%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $1.0B | $627M | $285M | $117M |
| Op margin | -13.3% | -49.3% | -185.2% | -389.4% |
| Net income | -$297M | -$177M | -$518M | -$446M |
| Gross margin | 60.3% | 62.6% | 49.4% | 44.1% |
| Gross profit | $621M | $393M | $141M | $51.6M |
| Operating income | -$137M | -$310M | -$528M | -$456M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · RBC Trims Price Target on Legend Biotech to $56 From $58, Keeps Outperform Rating
2026-10-04 · Legend Biotech (LEGN) Tests Its Valuation After Fresh CARVYKTI Five Year Data
2026-10-02 · Sector Update: Healthcare Stocks Steady Late Afternoon
2026-10-02 · Sector Update: Healthcare
2026-10-02 · Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says
2026-10-01 · Legend Biotech Insider Sold Shares Worth $258,920, According to a Recent SEC Filing
2026-09-29 · Asian Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
2026-09-25 · Legend Biotech Says Five-Year Carvykti Data Show 50% of Patients Remained Progression-Free and Alive
2026-09-25 · Can Legend Biotech (LEGN) Turn Cell Therapy Scale Into Compounding Wealth?
2026-09-15 · LEGN’s New CEO From Novartis Paves Way For Buyout Speculation
Price (daily)
Full chart · RSI · MACD · patterns